Interestingly, the anti-tumoral effect of dual inhibitors of SK1/SK2 activity [162] are now being investigated when SK1 and SK2 are both important therapeutic targets as in non-small cell lung cancer (NSCLC) [163]. The gene discussed is SPHK1; the disease is non-small cell lung carcinoma.